ImmunoGen, Inc. Announces Conference Call to Discuss Its Fourth Quarter and Fiscal Year 2016 Financial Results
July 21 2016 - 3:00PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company
developing novel antibody-drug conjugate (ADC) therapeutics, today
announced that the Company will host a conference call at 8:00 a.m.
ET on Thursday, August 4, 2016, to discuss ImmunoGen's financial
results for the three-month period and fiscal year ended June 30,
2016. Management also will provide an update on mirvetuximab
soravtansine and other ImmunoGen product programs.
To access the live call by phone, dial 913-312-1463; the
conference ID is 3243361. The call also may be accessed through the
Investors section of the Company's website, www.immunogen.com.
Following the live webcast, a replay of the call will be available
at the same location through August 18, 2016.
About ImmunoGen, Inc.
ImmunoGen is a clinical-stage biotechnology company that
develops targeted cancer therapeutics using its proprietary
antibody-drug conjugate (“ADC”) technology. ImmunoGen’s lead
product candidate, mirvetuximab soravtansine, is being advanced to
registration-enabling testing for FRα-positive platinum-resistant
ovarian cancer, and is also in Phase 1b/2 testing in
combination regimens for earlier-stage disease. ImmunoGen’s ADC
technology is used in Roche's marketed product, Kadcyla®, in three
other clinical-stage ImmunoGen product candidates, and in programs
in development by partners Amgen, Bayer, Biotest, CytomX, Lilly,
Novartis, Sanofi and Takeda.
Kadcyla® is a registered trademark of Genentech, a member
of the Roche Group.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160721006202/en/
ImmunoGen, Inc.Carol Hausner, 781-895-0600info@immunogen.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024